Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.59 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.59 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.59 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.56 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.56 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.56 |
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.46 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL266843 | 0.98 | HTR2A (0.61) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL46757 | 0.96 | HTR2A (0.63) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL12330478 | 0.86 | HTR2A (0.54) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL25949968 | 0.85 | TAAR1 (0.61) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL27361690 | 0.85 | HTR2A (0.53) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| Acetic Acid SCHEMBL3077099 | 0.85 | ACP3 (0.56) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| Hydrochloric Acid SCHEMBL7988615 | 0.84 | TAAR1 (0.65) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| Hydrochloric Acid SCHEMBL2124663 | 0.83 | IDO1 (0.63) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL13237463 | 0.82 | IDO1 (0.51) | IDO1HTR2AHTR2BHTR2CTAAR1 | |
| SCHEMBL429769 | 0.82 | TAAR1 (0.67) | IDO1HTR2AHTR2BHTR2CTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | H. LUNDBECK A/S (DK) | 2025-12-30 | — | — | US | disclosed |
| EP-4007571-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H LUNDBECK AS (DK) | 2025-06-18 | — | — | EP | disclosed |
| EP-4241843-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2025-05-21 | — | — | EP | disclosed |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-20220380300-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2022-12-01 | — | — | US | disclosed |
| US-20220280455-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. LUNDBECK A/S (DK) | 2022-09-08 | — | — | US | disclosed |
| EP-4007571-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. Lundbeck A/S (DK) | 2022-06-08 | — | — | EP | disclosed |
| WO-2021023616-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. LUNDBECK A/S (DK) | 2021-02-11 | — | — | WO | disclosed |
| US-10590067-B2 | Alcohol derivatives of carboxamides as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2020-03-17 | — | — | US | disclosed |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280455-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | KCNA7, KCNQ5, KCNQ2 | HTR2A 3535/4885HTR2B 2581/4885HTR2C 2644/4885 |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | HTR2A 2727/4885HTR2B 1900/4885HTR2C 1893/4885 |
| US-10590067-B2 | Alcohol derivatives of carboxamides as Kv7 potassium channel openers | KCNA7, KCNQ5, KCNQ1 | HTR2A 2704/4885HTR2B 1628/4885HTR2C 1513/4885 |
| US-20220380300-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | HTR2A 2727/4885HTR2B 1900/4885HTR2C 1893/4885 |
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | KCNN3, KCNN1, KCNN2 | HTR2A 1253/4885HTR2B 2436/4885HTR2C 1074/4885 |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | KCNA7, KCNK17, KCNQ1 | HTR2A 2727/4885HTR2B 1900/4885HTR2C 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.